Compare WAVE & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAVE | INTS |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 24.0M |
| IPO Year | 2021 | 2023 |
| Metric | WAVE | INTS |
|---|---|---|
| Price | $5.04 | $0.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $15.00 | $2.25 |
| AVG Volume (30 Days) | 12.2K | ★ 1.4M |
| Earning Date | 05-07-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $168,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $400.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.41 | $0.19 |
| 52 Week High | $9.88 | $2.50 |
| Indicator | WAVE | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 23.44 |
| Support Level | $4.95 | $0.34 |
| Resistance Level | $5.50 | $0.39 |
| Average True Range (ATR) | 0.40 | 0.02 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 54.74 | 4.46 |
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.